There are currently 1887 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC / Norris Comprehensive Cancer Center, Childrens Hospitla Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330
Recruiting
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Oruka Therapeutics Investigative Site, Los Angeles, California
Conditions: Plaque Psoriasis
Register for Updates
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990
Recruiting
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Site #0106, Los Angeles, California
Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
NCT05605093
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Cedars-Sinai Medical Center (Site 208-002), Los Angeles, California +1 locations
Conditions: COVID-19
Register for Updates
Study of Canakinumab in Patients With Myelofibrosis
NCT05467800
Recruiting
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles. Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California
Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
Register for Updates
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California
Conditions: Myelodysplastic Syndromes
Register for Updates
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/18/2025
Locations: Research Site, Los Angeles, California +1 locations
Conditions: Asthma
Register for Updates
Blue Light Cystoscopy With Cysview® Registry
NCT02660645
Recruiting
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +1 locations
Conditions: Bladder Cancer
Register for Updates
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332
Recruiting
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: UCLA Medical Center, Los Angeles, California +1 locations
Conditions: Metastatic Uveal Melanoma
Register for Updates
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156
Recruiting
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: UCLA David Geffen School of Medicine, Los Angeles, California
Conditions: Myelofibrosis
Register for Updates
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
NCT06188208
Recruiting
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: California Research Institute, Los Angeles, California
Conditions: Advanced Solid Tumors, Advanced Hematologic Tumors
Register for Updates
Strategy for Improving Stroke Treatment Response
NCT05948566
Recruiting
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Kaiser Permanente Los Angeles, Los Angeles, California
Conditions: Ischemic Stroke
Register for Updates
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446
Recruiting
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: David Geffen School of Medicine at UCLA, Los Angeles, California
Conditions: Myelodysplastic Syndromes
Register for Updates